nezeril 0,5 mg/ml nässpray, lösning
perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,5 mg/ml - oximetazolinhydroklorid 0,5 mg aktiv substans - oximetazolin
nezeril 0,5 mg/ml näsdroppar, lösning i endosbehållare
perrigo sverige ab - oximetazolinhydroklorid - näsdroppar, lösning i endosbehållare - 0,5 mg/ml - oximetazolinhydroklorid 0,5 mg aktiv substans - oximetazolin
nasin 0,5 mg/ml nässpray, lösning
perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,5 mg/ml - oximetazolinhydroklorid 0,5 mg aktiv substans; bensalkoniumklorid hjälpämne - oximetazolin
otrivin menthol (utan konserveringsmedel) 1 mg/ml nässpray, lösning
haleon denmark aps - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - sorbitol hjälpämne; makrogolglycerolhydroxistearat hjälpämne; xylometazolinhydroklorid 1 mg aktiv substans - xylometazolin
olynth 1 mg/ml nässpray, lösning
mcneil sweden ab - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - glycerol hjälpämne; xylometazolinhydroklorid 1 mg aktiv substans; sorbitol hjälpämne - xylometazolin
klarimax 1 mg/ml nässpray, lösning
orifarm generics a/s - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - xylometazolinhydroklorid 1 mg aktiv substans; sorbitol hjälpämne - xylometazolin
otrinex 1 mg/ml nässpray, lösning
haleon denmark aps - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - sorbitol hjälpämne; makrogolglycerolhydroxistearat hjälpämne; xylometazolinhydroklorid 1 mg aktiv substans - xylometazolin
otrivin comp 0,5 mg/ml + 0,6 mg/ml nässpray, lösning
haleon denmark aps - ipratropiumbromid (monohydrat); xylometazolinhydroklorid - nässpray, lösning - 0,5 mg/ml + 0,6 mg/ml - xylometazolinhydroklorid 0,5 mg aktiv substans; ipratropiumbromid (monohydrat) 0,6 mg aktiv substans; glycerol 85% hjälpämne - xylometazolin
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
osurnia
dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - kortikosteroider och antiinfectives i kombination - hundar - behandling av akut otitis externa.